{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:05:34Z","timestamp":1791821134066,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cholangiocarcinoma (CCA) still has a poor prognosis and remains a major therapeutic challenge. When curative resection is not possible, palliative systemic chemotherapy with gemcitabine and platinum derivate as first line followed by a 5-FU doublet combination as second line is the standard therapy. Recently, targeted therapy and immunotherapy have rapidly emerged as personalized therapeutic approaches requiring previous tumor sequencing and molecular profiling. BRCA mutations are well-characterized targets for poly (ADP-ribose) polymerase inhibitors (PARPi). However, BRCA gene mutations in CCA are rare and few data of PARPi in the treatment of CCA are available. Immunotherapy with programmed death receptor-1 (PD-1) has been shown to be effective in combination with chemotherapy or in PD-L1-positive CCA. However, data from immunotherapy combined with targeted therapy, including PARPi, are lacking. In this report, we present the case of a male patient with PD-L1-positive and BRCA2-mutated metastatic intrahepatic cholangiocarcinoma, who was treated with a combined therapy with PARP (PARPi), olaparib, and a PD-1 antibody, pembrolizumab, as second-line therapy after gemcitabine\/platinum derivate failure. Combined therapy was able to induce a long-lasting complete remission for over 15 months. The combined therapy was feasible and well tolerated. Only mild anemia and immune-related thyroiditis were observed, which were easily manageable and did not result in discontinuation of olaparib and pembrolizumab.<\/jats:p><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The presented case showed substantial clinical activity of a combination with olaparib\/pembrolizumab in advanced BRCA2-mutated CCA. Thus, identifying targetable molecular signatures and combinations of targeted therapies with immunotherapy reveals a promising strategy to effectively treat patients with cholangiocarcinoma and should be considered after failure of standard chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.933943","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T14:01:08Z","timestamp":1658757668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate"],"prefix":"10.3389","volume":"12","author":[{"given":"Taotao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00f6hring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farsaneh","family":"Sadeghlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieta","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Essler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Glowka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Matthaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg C.","family":"Kalff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Gonzalez-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the united states","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.6.816","article-title":"Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998","volume":"48","author":"Taylor-Robinson","year":"2001","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.11.015","article-title":"Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us","volume":"56","author":"Khan","year":"2012","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v2.i12.419","article-title":"Pathological classification of intrahepatic cholangiocarcinoma based on a new concept","volume":"2","author":"Nakanuma","year":"2010","journal-title":"World J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4642-9","article-title":"Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection","volume":"23","author":"Spolverato","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: Thirty-One-Year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.020","article-title":"Liver resection and transplantation for intrahepatic cholangiocarcinoma","volume":"72","author":"Mazzaferro","year":"2020","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2710","article-title":"Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41598-021-04297-2","article-title":"Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy","volume":"12","author":"Gonzalez-Carmona","year":"2022","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15050","article-title":"Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma","volume":"49","author":"Gonzalez-Carmona","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-007-0312-y","article-title":"Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience","volume":"12","author":"Gusani","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2013.03.019","article-title":"Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma","volume":"24","author":"Ray","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26407","article-title":"Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success","volume":"131","author":"Vogl","year":"2012","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: Expert consensus statement","volume":"17","author":"Weber","year":"2015","journal-title":"HPB (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (Pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"JCO"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.717397","article-title":"First line and second line chemotherapy in advanced cholangiocarcinoma and impact of dose reduction of chemotherapy: A retrospective analysis","volume":"11","author":"M\u00f6hring","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000038462.62634.B1","article-title":"The role of HER2\/neu Overexpression\/Amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast","volume":"15","author":"Latta","year":"2002","journal-title":"Mod Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B31","article-title":"Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: A 5-year experience with invasive ductal and lobular carcinomas","volume":"7","author":"Nassar","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i46.10254","article-title":"Response of BRCA1-mutated gallbladder cancer to olaparib: A case report","volume":"22","author":"Xie","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.10.011","article-title":"The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma","volume":"468","author":"Fehling","year":"2020","journal-title":"Cancer Lett"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: A multicenter retrospective study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7090054","article-title":"PARP inhibitors in biliary tract cancer: A new kid on the block","volume":"7","author":"Ricci","year":"2020","journal-title":"Medicines (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"17588359211036544","DOI":"10.1177\/17588359211036544","article-title":"IMbrave 151: A randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","volume":"13","author":"Hack","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability\/Mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0071","article-title":"PARP1 suppresses the transcription of PD-L1 by Poly(ADP-ribosyl)ating Stat3","volume":"7","author":"Ding","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.762989","article-title":"PARP inhibitor upregulates PD-L1 expression and provides a new combination therapy in pancreatic cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1758835920944116","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: Scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.5_suppl.48","article-title":"A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors","volume":"36","author":"Friedlander","year":"2018","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.452","article-title":"Phase II study of combination pembrolizumab and olaparib in patients with advanced cholangiocarcinoma: Interim results","volume":"40","author":"Yin","year":"2022","journal-title":"JCO"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S250454","article-title":"Olaparib and pembrolizumab treatment for BRCA1-mutated and PD-L1-Positive intrahepatic cholangiocarcinoma recurrence and metastasis: A case report","volume":"13","author":"Xiong","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17425247.2021.1825376","article-title":"Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: Preclinical and clinical studies and mechanism of action","volume":"18","author":"Xue","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.537","article-title":"Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer","volume":"51","author":"Shin","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000275","article-title":"Variation of programmed death ligand 1 expression after platinum-based neoadjuvant chemotherapy in lung cancer","volume":"42","author":"Guo","year":"2019","journal-title":"J Immunother"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","article-title":"Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer","volume":"464","author":"Fournel","year":"2019","journal-title":"Cancer Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): A phase 1\/2 study of niraparib + pembrolizumab in patients (Pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2013results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.100","article-title":"KEYNOTE-365 cohort a updated results: Pembrolizumab (Pembro) plus olaparib in docetaxel-pretreated patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Yu","year":"2020","journal-title":"JCO"},{"key":"B58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.140","article-title":"An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer","volume":"37","author":"Bang","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.933943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T14:01:12Z","timestamp":1658757672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.933943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":59,"alternative-id":["10.3389\/fonc.2022.933943"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.933943","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"article-number":"933943"}}